Fresenius Medical Care Corporation
- Industry Medical Care Facilities
- Sector Healthcare
- Market Cap
- Earnings
About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
FMS
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Warning: FMS is at high risk of cutting its dividend
- Fresenius stock rises as Q4 revenue grows, plans restructuring; sees 'headwinds' in FY23
- Fresenius Medical Care Q4 2022 Earnings Preview
- Fresenius considering deconsolidating dialysis subsidiary - Bloomberg
- Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed
- Fresenius Medical Care CFO takes over as CEO amid focus on 'operational turnaround'
- Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report
- Fresenius under pressure to make changes as activist Elliott takes 3% stake - Bloomberg
- Fresenius Q3 net income falls amid labor market woes, cuts FY22 outlook on slower recovery
- Fresenius Medical gains after report of activist Elliott stake in Fresenius SE
- Fresenius cut to Hold at Jefferies citing staffing issues and inflation
- Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
- Fresenius gets award to provide dialysis services to U.S. military veterans
- Fresenius appoints head of pharma unit as new CEO
- Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
- Vifor Fresenius' rare autoimmune disease drug Tavneos gets UK NICE backing
- DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation
- Fresenius stock slumps 13% as labor costs, inflation impact leads to FY22 outlook cut; 2025 targets withdrawn
- Fresenius slips as U.S. joins whistleblower lawsuit over Medicare fraud
- DaVita falls 10% after Supreme Court ruling in dialysis coverage case
PEERS
Earnings History
| Date | EPS / Forecast | Revenue / Forecast | |
|---|---|---|---|
| February 22, 2022 | 0.5101 / 0.4964 | 5.27B / 5.2B |
Beat! |
| November 2, 2021 | 0.5443 / 0.5523 | 5.14B / 5.3B | |
| July 30, 2021 | 0.4506 / 0.4728 | 5.12B / 5.21B | |
| May 6, 2021 | 0.5125 / 0.4748 | 5.09B / 5.1B | |
| February 23, 2021 | 0.7677 / 0.7588 | 5.35B / 5.6B | |
| October 29, 2020 | 0.7053 / 0.674 | 5.15B / 5.34B | |
| July 30, 2020 | 0.7077 / 0.62 | 5.37B / 5.23B |
Beat! |
| May 27, 2020 | 0.5212 / 0.48 | 4.92B / 4.84B |
Beat! |
| February 19, 2020 | 0.7339 / 0.65 | 4.91B / 5B | |
| October 29, 2019 | 0.67 / 0.66 | 4.91B / 4.91B | |
| July 30, 2019 | 0.92 / 0.56 | 4.35B / 4.85B | |
| July 29, 2019 | 0.47 / 0.55 | 4.84B / 4.85B | |
| May 1, 2019 | 0.58 / 0.53 | 4.61B / 4.58B |
Beat! |
| February 19, 2019 | 0.75 / 0.7 | 4.88B / 4.9B | |
| October 30, 2018 | 0.57 / 0.63 | 4.61B / 4.8B | |
| August 2, 2018 | 0.52 / 0.62 | 4.93B / 5.01B | |
| May 3, 2018 | 0.54 / 0.59 | 4.75B / 5.22B | |
| February 27, 2018 | - / 0.7 | - / 5.28B | |
| November 2, 2017 | 0.59 / 0.56 | 4.34B / 5.14B | |
| August 1, 2017 | 0.48 / 0.5 | 4.47B / 4.75B | |
| May 3, 2017 | - / 0.44 | 4.55B / - |
Beat! |
| February 22, 2017 | 0.64 / 0.62 | 4.69B / 4.74B | |
| October 27, 2016 | 0.54 / 0.52 | 4.60B / 4.60B |